0.07
—
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Invitro International
Its shares trade under the ticker IVRO. It has been listed since 16 May 1991. In the fiscal year to 30 September 2025, it reported revenue of $878,937 and net income of $121,980. At that date it held total assets of $2.0m and shareholders' equity of $1.7m.
InVitro International engages in the provision of non-animal testing methods. The company is headquartered in Placentia, California. Its products include Invitro Irritection and Corrositex. The Irritection assay system is a quantitative invitro test method that can be employed to detect, rank and predict the ocular and/or dermal irritation potential of cosmetics, consumer products, pharmaceuticals and chemical raw materials. Its corrositex is an invitro test that determines chemical corrosivity and permits assignment of packing group classification for Class 8 corrosives. The Irritection assay system provides an alternative to the traditional animal tests of ocular and/or dermal irritancy, and is considerably less expensive than in vivo tests. Its corrositex test replaces the rabbit test of dermal corrosivity by providing a means of mimicking this test.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 16 May 1991
- Employees
- 16
- Website
- invitrointl.com ↗
Leadership
Pay as last reported
- Irwin GruvermanChairman of the Board, since 1993
- W. Richard UlmerPresident, Chief Executive Officer, Director, since 1994$139,518
- Dennis ChenowethSenior Vice President, Director, since 1995$125,849
- William CurtisSecretary, Director, since 1985
- Mr. David ReedDirector
- Mr. Jeffrey SafchikDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Invitro International possesses several strengths that contribute to its success:
- Invitro International specializes in developing and manufacturing cutting-edge in vitro testing solutions, which allows it to offer accurate and reliable alternatives to animal testing.
Weaknesses
- Despite its strengths, Invitro International also faces certain weaknesses that could hinder its progress:
- Compared to some of its larger competitors, Invitro International may have lower market recognition, which could pose challenges in terms of customer acquisition and competition.
Opportunities
- There are several opportunities that Invitro International can leverage to further expand its business:
- With increasing concerns over animal welfare and regulatory pressure to reduce or replace animal testing, Invitro International can capitalize on the rising demand for its in vitro testing solutions.
Threats
- Invitro International should also be mindful of potential threats that could impact its growth and success:
- The market for in vitro testing solutions is becoming increasingly competitive, with new entrants and existing players continuously innovating. Invitro International must stay ahead of the competition to maintain its market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.